Back to School: How biopharma can reboot drug development. Access exclusive analysis here

sanofi-aventis' AVE5026 meets primary endpoint

sanofi-aventis (Euronext:SAN; SNY) said AVE5026 met the primary

Read the full 81 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE